Contraceptive Technology Update – April 1, 2003
April 1, 2003
View Issues
-
Hormone therapy: Make decisions on a balanced risk-to-benefit basis
Family planning clinicians have found their care of postmenopausal women has changed dramatically since the July 2002 cessation of the estrogen/progestin arm of the Womens Health Initiative (WHI). The estrogen/progestin arm of the landmark study was halted after findings showed that the overall health risk, particularly of cardiovascular disease and breast cancer, from taking estrogens with progestin was greater than the benefits of lowering the risk of colon cancer and bone fractures. -
Use the web for hormone therapy information
Check out the following Internet resources for more information on hormone therapy. -
Maintain confidential care for adolescents
Your practice includes confidential care for adolescents, including provision of contraceptives and testing/treatment for sexually transmitted diseases (STDs). But are your office staff communicating the confidentiality of this information correctly to prospective teen patients? If they are not, adolescents may fail to access these important services. -
The Pill and bone health: What is the impact?
Combined oral contraceptives (OCs) help decrease a womans risk for epithelial ovarian cancer and endometrial cancer, reduce her risk of pelvic inflammatory disease and ectopic pregnancy, and lessen menstrual cramps and pain. But what is their impact on bone mineral density (BMD)? -
Getting men on board: one facility’s approach
If the number of men on your patient rosters is low, take a look at the approach used by Planned Parenthood of San Antonio and South Central Texas. In the first year of its marketing initiative, the number of its male patients nearly doubled from 2% to 3.7% of total patients served. -
Ask the Experts: Answers to questions on OC use, DMPA impact
Whats the impact of concomitant medications on combined oral contraceptives (OCs)? -
CTU Updates
Enter abstracts for ARHP annual conference; New payment options announced for Mirena